← Leaderboards
Dennis J Hartigan-O'Connor
University Of California Los Angeles
$32,284,293
Attributed
$36,586,845
Total exposure
32
Grants
26
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $14.1M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$66,661,960 · 37
By mechanism
P01$26,820,318 · 12
R01$16,188,380 · 6
U42$14,081,487 · 2
U01$3,567,889 · 2
R21$1,536,972 · 4
R41$1,199,983 · 3
Top collaborators
- Alice F Tarantal19 shared
- David J Segal12 shared
- Rachel Lena Rutishauser4 shared
- Peter A Barry3 shared
- Kara W Chew2 shared
- Steven Grant Deeks2 shared
- Stephen Charles Noctor2 shared
- Ellen Elizabeth Sparger2 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Elizabeta Nemeth$12,940,270
- Sanjiv S Gambhir$44,452,033
- Kaleab Kidane Tessema$135,688
- Veena Sangkhae$760,525
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseNonhuman PrimateResponseCellsT-LymphocyteMacacaVirusInfectionVaccinesAnimalsT Cell ResponseSamplingMacaca MulattaViralVaccinationImmunityRegimenClinical TrialsMediatingEnsureInfantAdultVaccine TherapyImmune
Grant awards (101)
Optimal T-cell support for HIV neutralizing antibody induction to fusion peptide-inclusive regimens (Opti-FliP)$3,552,620
P01 · FY2025 · AI · contact PI
Multi-omic understanding of the transformed host T-cell response to HIV following therapeutic vaccination$1,549,574
P01 · FY2025 · AI · contact PI
A Phase 1/2a, randomized study of a Tfh-targeting genetic vaccine adjuvant designed to induce broad, durable immune responses$1,417,453
U01 · FY2025 · AI
Center for Somatic Cell Genome Editing in Nonhuman Primates$1,341,300
U42 · FY2025 · OD
Contributions of durable, high-avidity T-cell responses to protection achieved using the Opti-FliP vaccine regimen$1,260,330
P01 · FY2025 · AI · contact PI
Understanding reservoir effects and curative potential of a CD3/CCR5 bispecific antibody in infant macaques$788,984
R01 · FY2025 · AI · contact PI
Enhancing Rigor and Reproducibility of Translational Nonhuman Primate Models for Genetic and Regenerative Therapies$781,525
R01 · FY2025 · OD
Project 2$719,107
P01 · FY2025 · AI · contact PI
Validated Immunoassays to Accelerate Therapeutic Genome Editing INDs$715,222
U01 · FY2025 · AI
Impact of Maternal Inflammation and Cell Trafficking on Fetal Immune Ontogeny$678,065
R01 · FY2025 · HD
Project 1$486,037
P01 · FY2025 · AI · contact PI
Data Management and Analysis Core$267,100
P01 · FY2025 · AI · contact PI
Prevention of CMV infection with a viral IL-10 neutralizing antibody$232,415
R21 · FY2025 · AI · contact PI
Administrative Core$217,207
P01 · FY2025 · AI · contact PI
Administrative Core$77,330
P01 · FY2025 · AI · contact PI
Multi-omic understanding of the transformed host T-cell response to HIV following therapeutic vaccination$1,547,488
P01 · FY2024 · AI · contact PI
A Phase 1/2a, randomized study of a Tfh-targeting genetic vaccine adjuvant designed to induce broad, durable immune responses$1,435,214
U01 · FY2024 · AI
Center for Somatic Cell Genome Editing in Nonhuman Primates$1,341,300
U42 · FY2024 · OD
Enhancing Rigor and Reproducibility of Translational Nonhuman Primate Models for Genetic and Regenerative Therapies$781,525
R01 · FY2024 · OD
Project 2$779,124
P01 · FY2024 · AI · contact PI
Supplement to A Multi-omics Approach to Immune Responses in HIV Vaccination and Intervention$779,124
P01 · FY2024 · AI · contact PI
Understanding reservoir effects and curative potential of a CD3/CCR5 bispecific antibody in infant macaques$710,095
R01 · FY2024 · AI · contact PI
Impact of Maternal Inflammation and Cell Trafficking on Fetal Immune Ontogeny$678,065
R01 · FY2024 · HD
Project 1$640,229
P01 · FY2024 · AI · contact PI
BD FACSymphony S6$634,038
S10 · FY2024 · OD · contact PI
Project 2$622,668
P01 · FY2024 · AI · contact PI
Genetic adjuvants to elicit neutralizing antibodies against HIV$300,083
R43 · FY2024 · MH
Data Management and Analysis Core$202,125
P01 · FY2024 · AI · contact PI
Administrative Core$82,466
P01 · FY2024 · AI · contact PI
Nonhuman Primate Testing Center for Evaluation of Somatic Cell Genome Editing Tools$2,161,860
U42 · FY2023 · OD
Multi-omic understanding of the transformed host T-cell response to HIV following therapeutic vaccination$1,494,209
P01 · FY2023 · AI · contact PI
Center for Somatic Cell Genome Editing in Nonhuman Primates$1,341,300
U42 · FY2023 · OD
Effective CMV-based SIV vaccine regimens for newborn infants via IL-10 modulation$739,979
R01 · FY2023 · AI · contact PI
Project 2$625,293
P01 · FY2023 · AI · contact PI
Project 1$551,228
P01 · FY2023 · AI · contact PI
Genetic adjuvants to elicit neutralizing antibodies against HIV$300,930
R43 · FY2023 · MH
CCR5 immunotoxins as components of HIV cure regimens$300,000
R41 · FY2023 · AI · contact PI
Nonhuman Primate Testing Center for Evaluation of Somatic Cell Genome Editing Tools: Antibodies Supplement$241,224
U42 · FY2023 · OD
Data Management and Analysis Core$235,443
P01 · FY2023 · AI · contact PI
Administrative Core$82,245
P01 · FY2023 · AI · contact PI
Nonhuman Primate Testing Center for Evaluation of Somatic Cell Genome Editing Tools$2,551,595
U42 · FY2022 · OD
Improved RhCMV/SIV vaccine efficacy via IL-10 pathway modulation$1,326,960
R01 · FY2022 · AI · contact PI
LATC Collaborative Projects$1,002,488
U42 · FY2022 · OD
Effective CMV-based SIV vaccine regimens for newborn infants via IL-10 modulation$748,719
R01 · FY2022 · AI · contact PI
LATC Collaborative Project$365,885
U42 · FY2022 · OD
CCR5 immunotoxins as components of HIV cure regimens$300,000
R41 · FY2022 · AI · contact PI
SCGE Administrative Supplement$187,405
U42 · FY2022 · OD
Improved RhCMV/SIV vaccine efficacy via IL-10 pathway modulation$116,729
R01 · FY2022 · AI · contact PI
Nonhuman Primate Testing Center for Evaluation of Somatic Cell Genome Editing Tools$2,161,860
U42 · FY2021 · OD
Role of reservoir composition and T cell immunity in HIV rebound kinetics$1,393,523
P01 · FY2021 · AI · contact PI
LATC Collaborative Projects$1,057,357
U42 · FY2021 · OD
Effect of host immunity stimulated by viral IL-10-deleted RhCMV vaccines on SIV rebound$782,468
P01 · FY2021 · AI · contact PI
Improved RhCMV/SIV vaccine efficacy via IL-10 pathway modulation$761,860
R01 · FY2021 · AI · contact PI
Effective CMV-based SIV vaccine regimens for newborn infants via IL-10 modulation$757,677
R01 · FY2021 · AI · contact PI
SCGE Comparative Studies Supplement$327,913
U42 · FY2021 · OD
Memory-promoting Ad vaccine for long-lived protection against SARS-CoV-2$299,983
R41 · FY2021 · AI · contact PI
Vaccination with self-launching RhCMV/SIV DNA vaccine vectors$194,730
R21 · FY2021 · AI · contact PI
Administrative Core$40,985
P01 · FY2021 · AI · contact PI
Role of reservoir composition and T cell immunity in HIV rebound kinetics$1,378,787
P01 · FY2020 · AI · contact PI
Effective CMV-based SIV vaccine regimens for newborn infants via IL-10 modulation$778,922
R01 · FY2020 · AI · contact PI
Improved RhCMV/SIV vaccine efficacy via IL-10 pathway modulation$767,292
R01 · FY2020 · AI · contact PI
Effect of host immunity stimulated by viral IL-10-deleted RhCMV vaccines on SIV rebound$690,805
P01 · FY2020 · AI · contact PI
Nucleic acid-based formulation of cytomegalovirus-vectored HIV vaccines$300,000
R41 · FY2020 · AI · contact PI
Vaccination with self-launching RhCMV/SIV DNA vaccine vectors$233,432
R21 · FY2020 · AI · contact PI
Administrative Core$59,712
P01 · FY2020 · AI · contact PI
Role of reservoir composition and T cell immunity in HIV rebound kinetics$1,398,678
P01 · FY2019 · AI · contact PI
Improved RhCMV/SIV vaccine efficacy via IL-10 pathway modulation$773,435
R01 · FY2019 · AI · contact PI
Reservoir depletion and anti-retroviral therapy for infant functional cure$771,179
R01 · FY2019 · AI · contact PI
Effect of host immunity stimulated by viral IL-10-deleted RhCMV vaccines on SIV rebound$688,290
P01 · FY2019 · AI · contact PI
Administrative Core$81,131
P01 · FY2019 · AI · contact PI
Role of reservoir composition and T cell immunity in HIV rebound kinetics$1,415,389
P01 · FY2018 · AI · contact PI
Reservoir depletion and anti-retroviral therapy for infant functional cure$920,348
R01 · FY2018 · AI · contact PI
Improved RhCMV/SIV vaccine efficacy via IL-10 pathway modulation$791,333
R01 · FY2018 · AI · contact PI
Effect of host immunity stimulated by viral IL-10-deleted RhCMV vaccines on SIV rebound$679,055
P01 · FY2018 · AI · contact PI
Congenital Zika Syndrome and Postnatal Outcomes in Nonhuman Primates$231,600
R21 · FY2018 · NS
Administrative Core$92,998
P01 · FY2018 · AI · contact PI
Role of reservoir composition and T cell immunity in HIV rebound kinetics$1,484,236
P01 · FY2017 · AI · contact PI
Reservoir depletion and anti-retroviral therapy for infant functional cure$913,753
R01 · FY2017 · AI · contact PI
Effect of host immunity stimulated by viral IL-10-deleted RhCMV vaccines on SIV rebound$761,122
P01 · FY2017 · AI · contact PI
Congenital Zika Syndrome and Postnatal Outcomes in Nonhuman Primates$193,000
R21 · FY2017 · NS
Administrative Core$102,192
P01 · FY2017 · AI · contact PI
Reservoir depletion and anti-retroviral therapy for infant functional cure$932,148
R01 · FY2016 · AI · contact PI
Short and long-term effects of infant microbiota on (RhCMV) SIV vaccine efficacy$781,671
R56 · FY2016 · AI · contact PI
Reservoir depletion and anti-retroviral therapy for infant functional cure$669,787
R01 · FY2015 · AI · contact PI
Effective lethal agents for CCR5+ expressing cells$199,857
R21 · FY2015 · AI · contact PI
Effective lethal agents for CCR5???expressing cells$251,938
R21 · FY2014 · AI · contact PI
Regulatory T cell influence on infant and adult immune responses to HIV$124,200
K23 · FY2013 · AI · contact PI
Regulatory T cell influence on infant and adult immune responses to HIV$124,161
K23 · FY2012 · AI · contact PI
Regulatory T cell influence on infant and adult immune responses to HIV$39
K23 · FY2012 · AI · contact PI
Regulatory T cell influence on infant and adult immune responses to HIV$124,200
K23 · FY2011 · AI · contact PI
Regulatory T cell influence on infant and adult immune responses to HIV$124,200
K23 · FY2010 · AI · contact PI
Regulatory T cell influence on infant and adult immune responses to HIV$54,000
K23 · FY2010 · AI · contact PI
Regulatory T cell influence on infant and adult immune responses to HIV$124,200
K23 · FY2009 · AI · contact PI
IL-2 AND G-CSF FOR MAINTEN AND EXPANS OF REG T-CELLS IN NEONATAL RHES MACAQ$109,905
P51 · FY2009 · RR · contact PI
Regulatory T cell influence on infant and adult immune responses to HIV$49,139
K23 · FY2009 · AI · contact PI
IL-2 AND G-CSF FOR MAINTEN AND EXPANS OF REG T-CELLS IN NEONATAL RHES MACAQ$126,722
P51 · FY2008 · RR · contact PI
Impact of T-regulatory cells on SIV disease progression$51,548
F32 · FY2008 · AI · contact PI
IL-2 AND G-CSF FOR MAINTEN AND EXPANS OF REG T-CELLS IN NEONATAL RHES MACAQ$139,671
P51 · FY2007 · RR · contact PI
Impact of T-regulatory cells on SIV disease progression$49,928
F32 · FY2007 · AI · contact PI
Impact of T-regulatory cells on SIV disease progression$30,817
F32 · FY2005 · AI
Impact of T-regulatory cells on SIV disease progression$17,479
F32 · FY2005 · AI